Pfizer’s Strategic Pivot Gains Traction as Pipeline Progresses

Pharmaceutical giant Pfizer is navigating a critical strategic shift, moving decisively away from reliance on its declining COVID-19 business and toward new growth engines in oncology and obesity treatments. Recently confirmed financial guidance for 2025 and 2026 suggests this corporate transformation is beginning to yield results. Investors are now closely watching to see if the company’s development pipeline can successfully fill the revenue gap left by the fading pandemic-related products.

The market’s primary focus rests squarely on Pfizer’s research and development efforts. Just this Tuesday, the company released encouraging Phase 2b trial data for a novel weight-loss drug candidate. Acquired through the purchase of Metsera, the treatment demonstrated significant weight Read more...